Name

R-GemOx

Alternate names

GROC

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for R-GemOx

Name

Alternate Names

Anti-CD20 monoclonal antibodies
C2B8 monoclonal antibody
IDEC-C2B8
MabThera
Monoclonal antibody IDEC-C2B8
Rituxan

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic monoclonal antibody

NSC Number

687451

Primary Site

Leukemia
NHL

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.
FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.
FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.
FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.
FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who acheived response to rituximab in combination with chemotherapy.
June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
.

Coding

This drug should be coded

Name

Alternate Names

Gemcitabine Hydrochloride
Gemzar
LY 188011
LY-188011
LY188011 hydrochloride
Gemcitabine HCL

Abbreviations

None

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

613327

Primary Site

Bladder
Breast
non-small cell lung
ovarian
pancreatic cancer
Soft Tissue Sarcoma

Histology

None

Remarks

FDA approved for breast. ovarian, pancreas, NSC lung
Gemcitabine HCL is given intravesically as treatment for bladder tumors. Code as chemotherapy.

Coding

This drug should be coded

Name

Alternate Names

1-OHP
1670 RBl Eloxatin
Eloxatin
L-OHP
Oxalatoplatin
Oxalatoplatinum
PR-54780
RP-54780
Transplatin

Abbreviations

None

Category

Chemotherapy

Subcategory

Platinum analog

NSC Number

266046

Primary Site

Colorectal
gastro-esophageal cancers, metastatic
liver
ovarian
pancreatic cancer

Histology

None

Remarks

A platinum-containing antineoplastic that is usually given in combiantion with 5-FU.

Coding

This drug should be coded
Glossary